CARSGEN-B(02171.HK) closed 8.18% higher, the Hang Seng Pharmaceuticals & Biotechnology Sector saw divergent trends
NewTimeSpace News, By the close of trading on May 7, 2026, CARSGEN-B(02171.HK) saw a gain of 8.18% in its share price, closing at HKD 23.8. During the session, it reached an intraday high of HKD 24.18 and touched an intraday low of HKD 22. The full-day turnover stood at HKD 190.55 million, with significant volume growth, with the latest market capitalization at HKD 13.57 billion.
On the sector front, the Hang Seng Pharmaceuticals & Biotechnology Sector, to which CARSGEN-B belongs, showed an overall divergence trend, with 95 stocks advancing and 44 stocks declining.Among the gainers, WAI YUEN TONG closed higher by 10.77%, JW THERAP-B closed higher by 9.68%, CARSGEN-B closed higher by 8.18%, BIOCYTOGEN-B closed higher by 7.61%, GENSCRIPT BIO closed higher by 7.43%.Among the decliners, ZHONGZHIPHARM closed lower by 7.78%, IMMUNOTECH-B closed lower by 7.61%, INNOGEN-B closed lower by 6.24%, NT PHARMA closed lower by 5.88%, ZHONG JI LS closed lower by 5.75%.
NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CARSGEN-B (02171.HK): CT1190B and CT071 Abstracts Published at ASH 2026
- CARSGEN-B (02171.HK): Phase Ib Results of CT041 Consolidation Therapy in Gastric Cancer Presented at ESMO
- CARSGEN-B (02171.HK): First Patient Dose of CT0596 in China Phase I
- CARSGEN-B(02171.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 66.66 million, loss narrowed by 11.52% YoY
- CARSGEN-B (02171.HK): Universal CAR-T product CT1190B receives NMPA IND approval for treatment of relapsed/refractory large B-cell lymphoma